RVMDW

Investor Moves

Name	Value	Action	Change	Price	Current Price
Steven CohenPoint72 $-35.3M TrimQ1 2026 $35M $1.94 $8.62
Ken GriffinCitadel Advisors $-16.9M TrimQ1 2026 $17M $1.94 $8.62
Paul Tudor Jones IITudor Investment $1.2M AddQ1 2026 $1M $1.94 $8.62
Baillie GiffordInvestor $2.7M AddQ1 2026 $3M $1.94 $8.62
Jefferies GroupInvestor $-90.7M TrimQ1 2026 $91M $1.94 $8.62
Ken FisherFisher Asset Management $1.8M AddQ1 2026 $2M $1.94 $8.62

Insider Trades

Name	Value	Action	Price	Current Price
Mancini AnthonySee Remarks $308k2k shares SellMay 26, 2026 $154.06 $8.62
Mancini AnthonySee Remarks $107k700 shares SellMay 26, 2026 $153.30 $8.62
Mancini AnthonySee Remarks $65k421 shares SellMay 26, 2026 $154.82 $8.62
Mancini AnthonySee Remarks $220k1.7k shares SellApr 27, 2026 $131.66 $8.62
Mancini AnthonySee Remarks $139k1k shares SellApr 27, 2026 $132.88 $8.62
Mancini AnthonySee Remarks $54k400 shares SellApr 27, 2026 $134.34 $8.62

News

defenseworld.netRevolution Medicines, Inc. (NASDAQ:RVMDW) Sees Significant Increase in Short Interestdefenseworld.netApr 27

Trade RVMDW

About Revolution Medicines, Inc. Warrant

Revolution Medicines, Inc. is a biopharmaceutical company in the clinical development phase, concentrating on creating innovative, precisely targeted therapies for cancers driven by RAS pathway dysregulation. The firm's drug development portfolio features both RAS(ON) inhibitors, which are designed for potential use as single agents, in conjunction with other RAS(ON) inhibitors, or alongside RAS companion inhibitors and various therapeutic compounds. Additionally, its pipeline includes dedicated RAS companion inhibitors intended for synergistic treatment approaches. Among its RAS(ON) inhibitors currently in Phase 1 clinical trials are RMC-6236 (targeting a broad spectrum of RAS mutations), RMC-6291 (specific to G12C), and RMC-9805 (for G12D). Further compounds in preclinical or early development include RMC-5127 (for G12V), RMC-0708 (for Q61H), and RMC-8839 (for G13C), along with ongoing programs focused on G12R and other distinct molecular targets. In the realm of RAS companion inhibitors, RMC-4630 is advancing through Phase 2 clinical assessment, while RMC-5552 is undergoing Phase 1 evaluation. Revolution Medicines, Inc. was founded in 2014 and operates from its headquarters in Redwood City, California.

CEO: Mark A. Goldsmith
IPO Date: Feb 13, 2020

Market Data

Open: $0.386
High: $6.90
Low: $0.386
Volume: 28.8K
Avg Volume: 80.8K
52W High: $6.90
52W Low: $0.386

Valuation

Market Cap: $34.7B
Enterprise Value: $34.6B
Dividend Yield: 0.00%

Financials

Free Cash Flow: -$913.7M
Revenue: $0
Net Income: -$1.1B
Cash: $383.7M
Debt: $158.7M

Events

EarningsAug 12

EPS est. -1.96073